Live Breaking News & Updates on Indian Medical Products Agency
Stay updated with breaking news from Indian medical products agency. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lipidor : announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Update on Phase III Trial of AKP02 for Treating Psoriasis medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
(0) STOCKHOLM, April 22, 2021 /PRNewswire/ Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company s drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase III study. As Lipidor has previously announced, the main purpose of the study is to compare the therapeutic efficacy of AKP02 with existing medicines for mild to moderate psoriasis. Results from the study are expected in the first half of 2022. AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor s patented AKVANO technology. The aim with AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate plaque psoriasis. ....